Australien - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - nonacog alfa, quantity: 250 iu - injection, powder for - excipient ingredients: polysorbate 80; histidine; glycine; sucrose - benefix is indicated for the control and prevention of haemorrhagic episodes in patients with haemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings. benefix is not indicated for the treatment of other factor deficiencies (e.g. factors ii, vii and x), nor for the treatment of haemophilia a patients with inhibitors to factor viii, nor for the reversal of coumarin induced anti-coagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - influenza haemagglutinin recombinant, quantity: 45 microgram - injection, solution - excipient ingredients: dibasic sodium phosphate; sodium chloride; polysorbate 20; monobasic sodium phosphate; water for injections - flublok quadrivalent is indicated for active immunisation for the prevention of influenza disease caused by influenza virus types a and b contained in the vaccine. flublok quadrivalent is approved for use in persons 18 years of age and older.

USA - engelsk - NLM (National Library of Medicine)

baxter healthcare corporation - hyaluronidase recombinant human (unii: 743quy4vd8) (hyaluronidase recombinant human - unii:743quy4vd8) - hyaluronidase recombinant human 150 [usp'u] in 1 ml

USA - engelsk - NLM (National Library of Medicine)

a-s medication solutions - hyaluronidase (human recombinant) (unii: 743quy4vd8) (hyaluronidase (human recombinant) - unii:743quy4vd8) - hylenex recombinant is indicated as an adjuvant in subcutaneous fluid administration for achieving hydration. hylenex recombinant is indicated as an adjuvant to increase the dispersion and absorption of other injected drugs. hylenex recombinant is indicated as an adjunct in subcutaneous urography for improving resorption of radiopaque agents. hylenex recombinant is contraindicated in patients with known hypersensitivity to hyaluronidase or any of the excipients in hylenex recombinant. a preliminary skin test for hypersensitivity to hylenex recombinant can be performed. the skin test is made by an intradermal injection of approximately 0.02 ml (3 units) of a 150 unit/ml solution. a positive reaction consists of a wheal with pseudopods appearing within 5 minutes and persisting for 20 to 30 minutes and accompanied by localized itching. transient vasodilation at the site of the test, i.e., erythema, is not a positive reaction. discontinue hylenex recombinant if sensitization occurs. pregnancy category c. in an em

Den Europæiske Union - engelsk - EMA (European Medicines Agency)

intervacc ab - recombinant streptococcus equi protein cce, recombinant streptococcus equi protein eq85, recombinant streptococcus equi protein idee - immunologicals for equidae - horses - for the active immunisation to reduce clinical signs and the number of abscesses in acute stage of infection with s. equi.

Den Europæiske Union - engelsk - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - recombinant turkey herpesvirus, strain vhvt013-69, live - immunologicals for aves, domestic fowl, immunologicals - embryonated eggs; chicken - for active immunisation of chickens:to prevent mortality and to reduce clinical signs and lesions of infectious bursal disease.to reduce mortality, clinical signs and lesions of marek's disease.

New Zealand - engelsk - Ministry for Primary Industries

virbac new zealand limited - recombinant feline omega interferon - recombinant feline omega interferon 10,000 thou iu/ml - immune stimulant

USA - engelsk - NLM (National Library of Medicine)

guna spa - interleukin-12 human recombinant (unii: 02fxp10o2u) (interleukin-12 human recombinant - unii:02fxp10o2u) - interleukin-12 human recombinant 4 [hp_c] in 30 ml - interleukin-12   4c   anti-allergy immune support anti-allergy immune support take 15 minutes before meals.

Den Europæiske Union - engelsk - EMA (European Medicines Agency)

ceva-phylaxia co. ltd. - recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus, live - chicken - for active immunisation of chickens from 8 weeks of age in order to reduce the skin lesions due to fowlpox and to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis. 

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - recombinant respiratory syncytial virus pre-fusion f protein, quantity: 120 microgram - injection, powder for - excipient ingredients: sucrose; sodium chloride; mannitol; trometamol; trometamol hydrochloride; polysorbate 80 - abrysvo is indicated for:,? active immunisation of pregnant women between 24-36 weeks of gestation for prevention of lower respiratory tract disease caused by respiratory syncytial virus (rsv) in infants from birth through 6 months of age.,? active immunisation of individuals 60 years of age and above for prevention of lower respiratory tract disease caused by respiratory syncytial virus (rsv).,abrysvo should be used in accordance with official recommendations.